ArticleFrontiers in oncology2020
Volumetric Regression in Brain Metastases After Stereotactic Radiotherapy: Time Course, Predictors, and Significance.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Challenges of Applying the RANO-BM Criteria for Characterization of Brain Metastases Treatment Response.Current oncology (Toronto, Ont.) · 2026Review
- Temporal Dynamics and Heterogeneity in Brain Metastases: A Single-Center Retrospective Analysis of Vulnerabilities in Current MRI Surveillance Practices.Medicina (Kaunas, Lithuania) · 2026Observational
- Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies - a comprehensive review.Frontiers in oncology · 2026Review
- Reirradiation for recurrent glioblastoma: the significance of the residual tumor volume.Journal of neuro-oncology · 2025Article
- Exploratory Evaluation of Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) With Central Nervous System-Active Drugs in Brain Metastases Treatment.International journal of radiation oncology, biology, physics · 2025Article
- Temporal evolution of MRI findings and survival outcomes in patients with brain metastases after stereotactic radiosurgery.BMC medical imaging · 2025Article
- Paired molecular profiling of malignant transformation of an epidermoid cyst for potential genetic drivers: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Stereotactic radiosurgery for brain metastases secondary to adrenal ganglioneuroblastoma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Gradient-Based Radiomics for Outcome Prediction and Decision-Making in PULSAR: A Preliminary Study.International journal of particle therapy · 2025Article
- Quality of life after stereotactic radiosurgery for brain metastasis: an assessment from a prospective national registry.Journal of neuro-oncology · 2025Article
- Assessing tumor volumetric reduction with consideration for setup errors based on mathematical tumor model and microdosimetric kinetic model in single-isocenter VMAT for brain metastases.Physical and engineering sciences in medicine · 2024Article
- Multiomics-Based Outcome Prediction in Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR).Cancers · 2024Article
- Association of increasing gross tumor volume dose with tumor volume reduction and local control in fractionated stereotactic radiosurgery for unresected brain metastases.Radiation oncology (London, England) · 2024Article
- Correlating volumetric and linear measurements of brain metastases on MRI scans using intelligent automation software: a preliminary study.Journal of neuro-oncology · 2023Article
- Development of RLK-Unet: a clinically favorable deep learning algorithm for brain metastasis detection and treatment response assessment.Frontiers in oncology · 2023Article
- Volumetric reduction of brain metastases after stereotactic radiotherapy: Prognostic factors and effect on local control.Cancer medicine · 2022Article
- Article
- Deep Learning-Based Computer-Aided Detection System for Automated Treatment Response Assessment of Brain Metastases on 3D MRI.Frontiers in oncology · 2021Article
- The value of AI for assessing longitudinal brain metastases treatment response.Neuro-oncology advancesArticle
- Volumetric analysis: Rethinking brain metastases response assessment.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is insufficient understanding of the natural course of volumetric regression in brain metastases after stereotactic radiotherapy (SRT) and optimal volumetric criteria for the assessment of response and progression in radiotherapy clinical trials for brain metastases are currently unknown.
methodsVolumetric analysis
resultsMedian relative metastasis volume post-SRT was 66.9% at 6 weeks, 38.6% at 3 months, 17.7% at 6 months, 2.7% at 12 months and 0.0% at 24 months. Radioresistant histology and FSRT vs. SRS were associated with reduced tumor regression for all time points. In multivariate linear regression, radiosensitive histology (p=0.006) was the only significant predictor for metastasis regression at 3 months. Volumetric regression ≥20% at 3 months post-SRT was the only significant prognostic factor for subsequent control in multivariate analysis (HR 0.63, p=0.023), whereas regression ≥65% was no significant predictor.
conclusionsVolumetric regression post-SRT does not occur at a constant rate but is most pronounced in the first 6 weeks to 3 months. Despite decreasing over time, volumetric regression continues beyond 6 months post-radiotherapy and may lead to complete resolution of controlled lesions by 24 months. Radioresistant histology is associated with slower regression. We found that a cutoff of ≥20% regression for the volumetric definition of response at 3 months post-SRT was predictive for subsequent control whereas the currently proposed definition of ≥65% was not. These results have implications for standardized volumetric criteria in future radiotherapy trials for brain metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.